Need to Raise Additional Capital - Additional Information (Detail)		1 Months Ended		3 Months Ended
	May. 09, 2016	May. 11, 2016 USD ($)	Feb. 29, 2016 USD ($) Installment shares	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2015 USD ($)	[1]	Dec. 31, 2014 USD ($)
Need To Raise Additional Capital [Line Items]
Cash and cash equivalents				$ 4,502,000	$ 11,093,000	$ 7,755,000		$ 15,200,000
Working capital deficiency				$ (52,909,000)
Operating and capital plans				12 months
Proceeds from financing obligations				$ 1,000,000	$ 0
Teva Note [Member]
Need To Raise Additional Capital [Line Items]
Common stock shares issued upon debt conversion | shares			2,172,886
Reduction in outstanding balance of Notes			$ 5,000,000
Outstanding balance of notes			$ 20,000,000	$ 20,000,000
Number of annual consecutive payments | Installment			4
Annual consecutive payments amount			$ 5,000,000
Aggregate annual net sales of ADASUVE and Staccato enabled products			$ 50,000,000
Teva Note [Member] | Common Stock [Member]
Need To Raise Additional Capital [Line Items]
Common stock shares issued upon debt conversion | shares			2,172,886
Subsequent Event | Grupo Ferrer Internacional, S.A and Ferrer Pharma Inc., [Member]
Need To Raise Additional Capital [Line Items]
Merger agreement date	May 09, 2016
Subsequent Event | Ferrer Promissory Note Tranche Two [Member]
Need To Raise Additional Capital [Line Items]
Proceeds from financing obligations		$ 2,300,000

[1] The condensed consolidated balance sheet at December 31, 2015 has been derived from audited consolidated financial statements at that date.